Active Recombinant Human SLAMF7 protein, Fc/Avi-tagged, Biotinylated

• Cat.No.: SLAMF7-051H
• Product Overview: Biotinylated Recombinant Human SLAMF7(Ser23-Met226) protein, fused to Fc/Avi tag at the C-terminus, was expressed in HEK293 cells .

Specification

• Description: CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of an extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a transmembrane segment, and a cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% amino acid sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).Our Avi-tag Biotinylated Recombinant Human CRACC/SLAMF7 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.
• Source: HEK293 cells
• Species: Human
• Tag: Fc&Avi
• Predicted N Terminal: Ser23
• Form: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Bio-activity: The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.
• Molecular Mass: 65-85 kDa, under reducing conditions
• Protein length: Ser23-Met226
• Endotoxin: <0.10 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Applications: Binding Activity, Bioactivity
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 200 μg/mL in PBS.

Gene Information

• Gene Name: SLAMF7 SLAM family member 7 [ Homo sapiens ]
• Official Symbol: SLAMF7
• Synonyms: SLAMF7; SLAM family member 7; 19A; CD319; CRACC; CS1; protein 19A; CD2 subset 1; 19A24 protein; membrane protein FOAP-12; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; novel LY9 (lymphocyte antigen 9) like protein
• Gene ID: 57823
• mRNA Refseq: NM_021181
• Protein Refseq: NP_067004
• MIM: 606625
• UniProt ID: Q9NQ25

Reviews

07/28/2023

It has a high solubility and can be easily prepared at the desired concentration.

07/26/2021

It was found to be well active and could effectively perform the required biological activity experiments.

04/15/2020

It was observed that SLAMF7 had good crystallinity, which was conducive to crystallography research.

Q&As

What is the mechanism by which SLAMF7 protein regulates immune responses?

SLAMF7 protein is involved in regulating immune cell activation, proliferation, and transmission of background signals by binding to activating ligands, such as CD319, thereby influencing the immune response.

What is the potential of combining SLAMF7 protein with immunotherapy?

By combining with immunotherapy, such as anti-PD-1 antibodies, the immune response can be further enhanced and the anti-tumor effect can be improved. The study of SLAMF7 protein provides a new direction for the development of combinatorial therapeutic strategies.

In which tissues or cells is SLAMF7 protein expressed?

This protein is mainly expressed in the immune system, including immune cells such as plasma cells, NK cells, and activated T cells.

Does the SLAMF7 protein have a similar role in other types of cancer?

The role of SLAMF7 protein in other types of cancer is unclear, and further research is needed to determine its potential role in other cancers.

Does SLAMF7 protein have potential in the treatment of multiple myeloma?

Yes, the SLAMF7 protein has been shown to be a potential therapeutic target. A monoclonal antibody drug targeting SLAMF7 protein (Elotuzumab) has been developed for the treatment of multiple myeloma.

What is the function of SLAMF7 protein in multiple myeloma?

SLAMF7 protein interacts with NK cells in multiple myeloma and plays a role in inhibiting and controlling tumor growth by activating the anti-tumor activity of NK cells.